uniQure NV股价大涨，公司称其亨廷顿病基因疗法可在开展新研究前寻求美国批准。
据 Bloomberg 报道，这一逆转显示特朗普政府正放松此前对药物审评的强硬立场。
股票市场 | uniQure称亨廷顿疗法可先申报FDA
2026-06-17 14:33:14
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
美国证交会拟取消股票“穿透交易”规则
